115 related articles for article (PubMed ID: 8836426)
1. Treatment of Hodgkin's disease with bispecific antibodies.
Hartmann F; Renner C; Jung W; Sahin U; Pfreundschuh M
Ann Oncol; 1996; 7 Suppl 4():143-6. PubMed ID: 8836426
[TBL] [Abstract][Full Text] [Related]
2. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
3. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
4. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
5. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
6. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
[TBL] [Abstract][Full Text] [Related]
8. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.
Arndt MA; Krauss J; Kipriyanov SM; Pfreundschuh M; Little M
Blood; 1999 Oct; 94(8):2562-8. PubMed ID: 10515858
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.
Sahin U; Kraft-Bauer S; Ohnesorge S; Pfreundschuh M; Renner C
Cancer Immunol Immunother; 1996 Jan; 42(1):9-14. PubMed ID: 8625370
[TBL] [Abstract][Full Text] [Related]
10. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Jung W; Deisting C; Juwana M; Pfreundschuh M
Cancer Immunol Immunother; 2000 Jun; 49(3):173-80. PubMed ID: 10881697
[TBL] [Abstract][Full Text] [Related]
11. Tumor therapy by immune recruitment with bispecific antibodies.
Renner C; Pfreundschuh M
Immunol Rev; 1995 Jun; 145():179-209. PubMed ID: 7590826
[TBL] [Abstract][Full Text] [Related]
12. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Renner C; Hartmann F; Pfreundschuh M
Cancer Immunol Immunother; 1997; 45(3-4):184-6. PubMed ID: 9435869
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody.
Hartmann F; Renner C; Jung W; Deisting C; Juwana M; Eichentopf B; Kloft M; Pfreundschuh M
Blood; 1997 Mar; 89(6):2042-7. PubMed ID: 9058726
[TBL] [Abstract][Full Text] [Related]
14. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma.
Borchmann P; Schnell R; Schulz H; Engert A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1262-7. PubMed ID: 15648946
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.
Sundarapandiyan K; Keler T; Behnke D; Engert A; Barth S; Matthey B; Deo YM; Graziano RF
J Immunol Methods; 2001 Feb; 248(1-2):113-23. PubMed ID: 11223073
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
Hartmann F; Renner C; Jung W; Pfreundschuh M
Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
[TBL] [Abstract][Full Text] [Related]
18. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
Cancer Res; 1990 Nov; 50(21):6944-8. PubMed ID: 2170012
[TBL] [Abstract][Full Text] [Related]
19. Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
Fisher RI
Clin Cancer Res; 2001 Jul; 7(7):1835-6. PubMed ID: 11448891
[No Abstract] [Full Text] [Related]
20. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]